Literature DB >> 23334604

Cannabinoid receptor 1 inhibition improves the intestinal microcirculation in experimental endotoxemia.

Mandana Kianian1, Melanie E M Kelly2, Juan Zhou3, Orlando Hung1, Vladimir Cerny4, Geoffrey Rowden5, Christian Lehmann6.   

Abstract

INTRODUCTION: Impairment of the intestinal microcirculation in endotoxemia may cause a deterioration of the mucosal barrier function thus releasing intraluminal bacteria and their toxins into the systemic circulation. In clinical sepsis this mechanism may influence disease severity and outcome. The aim of the study was to investigate the impact of cannabinoid receptor 1 (CB1R) modulation within the intestinal microcirculation with regard to leukocyte activation and capillary perfusion, and on intestinal histology in experimental endotoxemia in rats.
METHODS: Endotoxemia was induced by intravenous lipopolysaccharide (LPS) administration. We studied 5 groups of animals: controls (CON), LPS, LPS + CB1R agonist (ACEA, 2.5 mg/kg), LPS + CB1R antagonist (AM281, 2 mg/kg) and LPS + CB1R agonist (ACEA, 2.5 mg/kg) + CB1R antagonist (AM281, 2 mg/kg). Intestinal intravital microscopy (IVM) was performed two hours following LPS/placebo administration. Intestinal leukocyte adhesion in submucosal venules and functional capillary density (FCD) of the intestinal wall was quantified using IVM. Histological changes were assessed using a standardized injury score.
RESULTS: After two hours of endotoxemia, we observed a significant increase of leukocyte adhesion in intestinal submucosal venules. Administration of the CB1R antagonist in endotoxemic animals significantly reduced the number of adhering leukocytes (p < 0.05). The CB1R agonist did not further increase leukocyte adhesion. FCD was significantly improved by the CB1R antagonist (p < 0.05). Administration of the CB1R agonist, ACEA, reversed the beneficial effect of the CB1R antagonist, AM281.
CONCLUSIONS: CB1R inhibition significantly improved intestinal microcirculation by reducing leukocyte adhesion and increasing FCD in acute endotoxemia in rats. The data supports the involvement of the CB1R signaling in leukocyte activation during sepsis. Drugs targeting the CB1R may have therapeutic potential in systemic inflammation, such as sepsis.

Entities:  

Keywords:  Sepsis; cannabinoid receptor; endotoxemia; intestine; intravital microscopy; leukocyte adherence; microcirculation

Mesh:

Substances:

Year:  2014        PMID: 23334604     DOI: 10.3233/CH-131668

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  6 in total

1.  Cannabinoid receptors in mantle cell lymphoma.

Authors:  Agata M Wasik; Birgitta Sander
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Intestinal microcirculation dysfunction in sepsis: pathophysiology, clinical monitoring, and therapeutic interventions.

Authors:  A-Ling Tang; Mei-Jia Shen; Guo-Qiang Zhang
Journal:  World J Emerg Med       Date:  2022

3.  Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Authors:  Agata M Wasik; Lina Nygren; Stefan Almestrand; Fang Zong; Jenny Flygare; Stefanie Baumgartner Wennerholm; Leonie Saft; Patrik Andersson; Eva Kimby; Björn E Wahlin; Birger Christensson; Birgitta Sander
Journal:  Oncoscience       Date:  2014-09-04

Review 4.  CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation.

Authors:  Juan Zhou; Ian Burkovskiy; Hyewon Yang; Joel Sardinha; Christian Lehmann
Journal:  Front Pharmacol       Date:  2016-08-22       Impact factor: 5.810

Review 5.  Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy.

Authors:  Juan Zhou; Kiyana Kamali; J Daniel Lafreniere; Christian Lehmann
Journal:  Cannabis Cannabinoid Res       Date:  2021-05-27

6.  Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis.

Authors:  J Sardinha; M E M Kelly; J Zhou; C Lehmann
Journal:  Mediators Inflamm       Date:  2014-04-03       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.